Identification of the P2Y_{12} receptor in nucleotide inhibition of exocytosis from bovine chromaffin cells

Steven J. Ennion*, Andrew D. Powell* and Elizabeth P. Seward

* These authors contributed equally to the work.

Department of Cell Physiology and Pharmacology, University of Leicester, (SJE),
Department of Pharmacology, University of Bristol, (ADP), Department of Biomedical Sciences, University of Sheffield (EPS).
Running Title: P2Y₁₂ mediated inhibition of exocytosis

Corresponding author:
Dr Elizabeth P. Seward
Institute of Molecular Physiology,
University of Sheffield,
Alfred Denny Building,
Western Bank,
Sheffield,
S10 2TN, U.K.
Tel: (44) 114-222-2383 FAX: (44) 114-222-2360
E-mail: e.p.seward@sheffield.ac.uk

Text pages: 31
Tables: 2
Figures: 8
References: 40

Words in Abstract (250 word limit): 197
Words in Introduction (750 word limit): 633
Words in Discussion: (1500 word limit): 1312

Non-standard abbreviations:

VOCC: Voltage operated Ca²⁺ channel
I_Ca: Ca²⁺ current
C_m: membrane capacitance
PPADS: Pyridoxal-phosphate-6-azophenyl-2’,4’ disulfonic acid
2-MeSATP: 2-methylthioadenosine 5’- triphosphate
2-MeSADP: 2-methylthioadenosine 5’- diphosphate
PTX: Pertussis toxin
ARC69931MX: N⁶-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-β,γ-dichloromethylene ATP
ABSTRACT

Nucleotides are released from bovine chromaffin cells and take part in a feedback loop to inhibit further exocytosis. In order to identify the nucleotide receptors involved, we measured the effects of a range of exogenous nucleotides and related antagonists on voltage-operated calcium currents ($I_{Ca}$), intracellular calcium concentration ([Ca$^{2+}$]$_i$), and membrane capacitance changes ($\Delta C_m$). In comparative parallel studies we also cloned the bovine P2Y$_{12}$ receptor from chromaffin cells, and determined its properties by co-expression in *Xenopus* oocytes with inward-rectifier potassium channels made up of Kir3.1 and Kir3.4. In both systems, the agonist order of potency was essentially identical (2-MeSATP $\approx$ 2-MeSADP $\gg$ ATP $\approx$ ADP $>$ UDP). $\alpha\beta$Methylene-ATP and adenosine were inactive. UTP inhibited $I_{Ca}$ in chromaffin cells (pEC$_{50}$ 4.89 ± 0.11) but was essentially inactive at the cloned P2Y$_{12}$ receptor. The relatively non-selective P2 antagonist pyridoxal-phosphate-6-azophenyl-2',4' disulfonic acid (PPADS) blocked nucleotide responses in both chromaffin cells and *Xenopus* oocytes, whilst the P2Y$_{12}$ and P2Y$_{13}$ selective antagonist, ARC69931MX blocked responses to ATP in both chromaffin cells and *Xenopus* oocytes but not to UTP in chromaffin cells. These results identify the P2Y$_{12}$ purine receptor as a key component of the nucleotide inhibitory pathway, and also demonstrate the involvement of a UTP sensitive $G_{i/o}$ coupled pyrimidine receptor.
Given the profusion of P2 nucleotide receptors in the nervous system and the many pathways for nucleotide release, the potential for extracellular nucleotides to play a major modulatory role in neurotransmission is high. Based on their structure and signalling mechanisms, P2 receptors are classified as either ligand gated P2X_{1-7} cation channels or as metabotropic P2Y_{1,2,4,6,11-15} receptors coupled to heterotrimeric G proteins (North, 2002; Abbracchio et al., 2003, Inbe et al., 2004). Activation of P2X receptors by ATP leads directly to membrane depolarisation and calcium entry both via the P2X channels themselves and also by the subsequent activation of VOCCs (voltage-operated calcium channels) (North, 2002). P2Y receptors have a wider agonist profile than the P2X receptors responding to purines, pyrimidines and UDP-glucose. These receptors can be divided into two subgroups based on their molecular structure and coupling to G\_{\alpha}-subunits, with P2Y_{12}, P2Y_{13} and P2Y_{14} making up one group which signal via PTX-sensitive G_{i/o} proteins, and P2Y_{1}, P2Y_{2}, P2Y_{4}, P2Y_{6}, P2Y_{11} and P2Y_{15} making up the second group, coupling to phospholipase C and G proteins of the G_{q/-} class (Abbracchio et al., 2003; Inbe et al., 2004).

In the sympathetic nervous system, the effects of presynaptic purine receptors on neurotransmission have been well documented; facilitation of catecholamine release is mediated by P2X receptors, whilst inhibition is mediated by the activation of an unidentified P2Y receptor (Von Kügelgen et al. 1989; Boehm and Kubista, 2002). Evidence for inhibitory presynaptic P2Y receptor(s) regulating release of catecholamine as well as other neurotransmitters in the central nervous system is also accumulating (Cunha and Ribeiro 2000; Zhang et al. 2003). Identifying which nucleotide receptor subtypes mediate presynaptic inhibition has been complicated by the inaccessibility of the majority of mammalian nerve terminals, complexity arising from neural circuits where multiple P2 receptors may be activated, stimulation of P1 adenosine receptors following breakdown of purines by
ectonucleotidases, and the limited availability of P2 receptor subtype selective agonists and antagonists.

Adrenal chromaffin cells are embryonically derived from precursors of sympathetic neurones, they also release catecholamines and ATP by Ca\(^{2+}\) regulated exocytosis and express inhibitory P2 receptors that couple to neuronal VOCCs (Diverse-Pierluissi et al. 1991; Gandia et al. 1993; Currie and Fox 1996). Moreover, evidence for an autocrine feedback loop similar to that proposed for sympathetic neurones involving an inhibitory P2Y-like receptor has been reported (Carabelli et al. 1998). In a previous study, we used combined C\(_m\) measurements and voltage-clamp recordings to examine the mechanisms underlying purinergic inhibition of exocytosis in chromaffin cells (Powell et al., 2000). We showed that the purine analogue 2-MeSATP inhibits Ca\(^{2+}\) entry through N- and P/Q-type VOCCs and consequently, stimulus-evoked changes in C\(_m\) through a PTX-sensitive G protein. The aim of this study was to expand on this finding by determining the molecular identity of the P2Y receptor(s) involved. Here we provide evidence for two inhibitory PTX-sensitive G\(_{i/o}\)-coupled P2Y receptors in bovine chromaffin cells. One of these receptors shows a pharmacology similar, but not identical (ATP being a full agonist and equipotent to ADP) to the human P2Y\(_{12}\) receptor, whilst the second receptor is UTP sensitive and hence shows a pharmacology not matching any of the known G\(_{i/o}\)-coupled P2Y receptors. In order to confirm the role of P2Y\(_{12}\) in VOCC inhibition, we cloned the bovine P2Y\(_{12}\) receptor from bovine chromaffin cells and expressed this receptor in *Xenopus* oocytes co-expressing inward-rectifier potassium channels made up of rat Kir3.1 and Kir3.4. The pharmacological properties of this cloned receptor closely mirrored the pharmacology observed in chromaffin cells except that UTP was a very weak partial agonist. We therefore conclude that P2Y\(_{12}\) and another as of yet unidentified G\(_{i/o}\)-protein coupled UTP-sensitive receptor inhibit VOCCs and exocytosis in chromaffin cells.
These findings support the view that Gi/o coupled P2Y receptors may also act as presynaptic inhibitory receptors in other neuronal systems to regulate neurotransmitter release.

MATERIALS AND METHODS

Chromaffin cell culture- Chromaffin cells were prepared by collagenase digestion of bovine adrenal glands as previously described (Powell et al., 2000). Adrenal glands from 18-24 month old cows were obtained from a local abattoir and retrogradely perfused at 25 ml/min for 30 min at 37 °C with the digestive enzymes collagenase type 2 (0.03 %) (Worthington Biochemical Corp., Lakewood, NJ) and DNase I (0.0013 % ) (Boehringer Mannheim Biochemicals, Indianapolis) added to Locke’s solution (154.2 mM NaCl, 2.6 mM KCl, 2.2 mM K2HPO4, 0.85 mM KH2PO4, 10 mM glucose, 5 mM HEPES, 0.0005 % Phenol Red (Gibco BRL, Paisley, UK); pH adjusted to 7.2 with NaOH). After surgical removal of the cortex, the medulla was dissected, cut into small pieces, placed in a trypsinisation flask with fresh enzyme solution and stirred at slow speed for 30 min at 37 °C. Cells were washed twice with Earle’s Balanced Salt Solution (Gibco BRL) and resuspended in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco BRL) supplemented with 44 mM NaHCO3, 15 mM HEPES, 10% fetal calf serum (Gibco BRL), 1% glutamine, 1% penicillin-streptomycin solution, 2.5 mg/ml gentamycin, 0.5 mg/ml 5’-fluorodeoxyuridine, and 0.01 mg/ml cytosine-β-δ-arabinofuranoside. Cells were plated on glass cover slips coated with matrigel (Becton Dickinson Labware, Bedford, MA) at an approximate density of 800 cells/mm². Approximately 80% of the media was replaced 24 hr after plating and cells were maintained for up to 7 days in a humidified atmosphere of 95% O2 / 5% CO2 at 37 °C.

[Ca2+]i measurements in bovine chromaffin cells- Cells were loaded with the Ca2+ indicator Fura 2-AM by addition of 5 µM Fura-2/AM (Molecular Probes) to DMEM medium and
incubated for 25 min at 37 ºC. Cells were then washed with fresh DMEM and incubated a
further 15 min at 37 ºC. Isolated fluorescent chromaffin cells were alternately illuminated at
340 nm and 380 nm using a monochromator (TILL Photonics, Gräfelfing, Germany)
controlled by the data acquisition software. Emission >430 nm was collected with a
photomultiplier tube (TILL Photonics) and sampled approximately every 12 ms. Data were
stored on PC and ratios of 340/380 nm were calculated off-line (Axobasic-written software).

Electrophysiological recordings in bovine chromaffin cells- A cover slip carrying chromaffin
cells was placed in a micro-perfusion chamber (~200µl volume) on the stage of an inverted
phase-contrast microscope (Nikon, Diaphot 200). Cells were continuously superfused with an
external solution consisting of 130 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM CaCl2, 10 mM
glucose and 10 mM HEPES, adjusted to pH 7.2 with NaOH, osmolarity ~280 mOsm. Special
care was taken to superfuse cells at a high rate (~ 3 ml/min) throughout the experiment and to
select well isolated single cells for recording in order to avoid compounding effects of
endogenously released modulators (Carabelli et al., 1998). Ionic currents were recorded in
whole-cell or perforated patch clamp configuration using borosilicate glass electrodes coated
with Sylgard 184 (Dow Corning, Midland, MI) and fire polished on a microforge to a
resistance of 1-2 MΩ. Electrodes were filled with an internal solution consisting of 145 mM
Cs-glutamate (Calbiochem, Nottingham, UK), 10 mM HEPES, 9.5 mM NaCl, 0.3 mM bis(2-
aminophenoxy)ethane-N,N,N',N'-tetra-acetic acid (BAPTA; Molecular Probes, Eugene, OR),
adjusted to pH 7.2 with CsOH (ICN Biomedicals Inc., Aurora, OH); osmolarity ~ 280 mOsm.
For whole-cell recording experiments, 2mM Mg-ATP was added to the internal solution to
prevent rundown of VOCCs and exocytosis. Gramicidin D (Sigma, Poole, U.K.) at a final
concentration of 9.7 µg/ml was used for perforation. For both whole-cell and perforated-patch
recordings, series resistance was less than 12 MΩ and compensated (typically > 70%)
electronically with the patch-clamp amplifier (Axopatch 200B; Axon Instruments, Foster City, CA). Voltage protocol generation and data acquisition were performed using custom data acquisition software (kindly provided by Dr. A. P. Fox, University of Chicago) running on a Pentium computer equipped with a Digidata 1200 acquisition board (Axon Instruments). Current traces were low pass filtered at 5 kHz using the four-pole Bessel filter of the amplifier and digitized at 10 kHz. Chromaffin cells were voltage-clamped at -90 mV and $C_m$ was sampled with a resolution of 12 ms using a software-based phase-tracking method as described previously (Fidler and Fernandez, 1989; Powell et al., 2000). Data were stored on the computer hard drive and analysed off-line using self-written (Axobasic; Axon Instruments) and commercial (Origin, Microcal, Northampton, MA) software. All experiments were performed at ambient temperature (21-25°C).

Cloning of the bovine P2Y$_{12}$ receptor- The strategy used to clone the bovine P2Y$_{12}$ receptor consisted of three sequential rounds of cloning. Firstly a conserved central region of the receptor was amplified by PCR (Polymerase chain reaction) with degenerate primers (PCR1). Secondly, 5’ and 3’RACE (Rapid amplification of cDNA ends) primers were designed from the sequence obtained from PCR product 1 and used to amplify the 5’ and 3’ ends of the receptor by 5’ and 3’ RACE respectively (PCRs 2 and 3). Finally, sequence obtained from PCR products 2 and 3 was used to design primers to amplify the full length receptor from bovine chromaffin cell cDNA by RT-PCR. A proof reading polymerase (Bio-X-Act, Bioline, U.K) was used for all PCR reactions. Total RNA was prepared from bovine chromaffin cells and 5µg was used in a first strand cDNA reaction using RoRidT$_{(17)}$ primer (Harvey and Darlison, 1991) and Superscript II reverse transcriptase according to the manufacturers instructions (Amersham, U.K.). The degenerate primers for PCR 1, y12degF (5’TTTCTGTGGYCATCTGGCCMTTCATG 3’) and y12degR
(5’GGTCACCACCWTCYTGTYCTTTYTTC 3’) were designed based on homologous regions of the human mouse and rat P2Y12 sequences (Accession numbers NM_022788, AK013804 and NM_022800 respectively). 5’ RACE (PCR 2) was performed using a SMART™ RACE kit (Clontech U.S.A) according to the manufacturers instructions with the sequence specific primer TEW81 (5’ GCCAAACCAGACCAACTCTGACTTCAG 3’) designed from the sequence of PCR 1. 3’ RACE (PCR 3) was performed utilising the primers Ro (Harvey and Darlison, 1991), and bY12RACEfor (5’ GGTGCTGGCAAGGTCCCCAAGAA 3’). The primers 2ndby12fullfor (5’ GACGGAAATACAGTGTCTGC 3’) and 2ndby12fullrev (5’ CTTGCCTTTGGGGAGTT 3’) were designed from the sequence obtained from PCRs 1 and 2 and utilised in RT-PCR to amplify the full length P2Y12 receptor from first strand cDNA prepared from bovine chromaffin cells. PCR products were cloned into the plasmid pCDNA3 (Invitrogen USA) and two independent colonies sequenced on both strands (Automated ABI sequencing service, Protein and Nucleic acid Laboratory, University of Leicester).

**RT-PCR analysis**- RT-PCR was performed on first strand cDNA prepared from bovine chromaffin cells as described above. The only published bovine P2Y sequence available for primer design was that of P2Y1 (Henderson et al., 1995). BLAST homology searches of the bovine EST database found sequences corresponding to the bovine P2Y2, 6 and 14 receptors (Accession numbers BM031311, BI680595 and CB429080 respectively). Allowing the presence of transcripts for P2Y1, 2, 6, 12, and 14 to be analysed in addition to the published bovine P2Y1 (Primer sequences in Table 1).

**Electrophysiological recordings in Xenopus oocytes**- Xenopus oocytes expressing the rat inwardly rectifying potassium channels Kir 3.1 and Kir 3.4 were used to assess the function of
the cloned bovine P2Y12 receptor in a system similar to that utilised by Hollopeter and co-
workers to characterise the human P2Y12 receptor (Hollopeter et al., 2001). Plasmids for rat
Kir 3.1 and Kir 3.4 were a kind gift from Prof M. Boyett. cRNA was transcribed from
linearized P2Y12, Kir 3.1 and Kir 3.4 plasmids using the mMessage mMachine™ system
(Ambion, U.S.A) according to the manufacturers instructions. De-folliculated stage V-VI
Xenopus oocytes were injected with 1.25ng Kir 3.1, 1.25ng Kir 3.4 and 50 pg P2Y12 cRNA in
a total volume of 50 nl using an Inject +Matic micro injector (J.Alejandro Gaby, Genéva).
Oocytes were stored at 18 °C in ND96 buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1
mM MgCl2, 5 mM sodium pyruvate, 5 mM HEPES, pH 7.6) prior to use 3-7 days later.

Two-electrode voltage clamp recordings were made from oocytes using a Turbo TEC
10C amplifier (NPI Electronic Instruments, Germany) with a Digidata 1200 analogue to
digital converter (Axon Instruments U.S.A,) and WinWCP acquisition software (Dr J.
Dempster University of Strathclyde, Scotland). Agonists and antagonists were bath perfused
using a custom built rapid exchange perfusion system. Oocytes were initially perfused with
ND96 in order to obtain a value for the resting membrane potential (typically ~ -70mV for Kir
injected oocytes, and ~ -20mV for non-injected or P2Y12 only injected oocytes) before
exchange to 70K solution (20mM NaCl, 70mM KCl, 3 mM MgCl2 5mM HEPES) for
recording of agonist evoked membrane currents. Agonist evoked currents could be measured
in oocytes clamped constantly at – 60mV, however, the current required (~5 μA) to clamp at
this potential tended to kill cells after ~15-30 minutes. Therefore, in order to obtain full
concentration response curve data for individual cells, oocytes were clamped at 0 mV during
the initial period of agonist application and in recovery periods between applications. One
minute after agonist application commenced, the holding potential was stepped down to -
60mV for 5 seconds and the peak current recorded. A ramp from -60mV to +90mV over 2
seconds was applied after the 5 second recording period in order to visualise the inward
rectification from the Kir channels, verifying that the cell was still in a healthy condition. Currents in the presence of agonist were normalised to the mean of recordings taken 5 minutes prior and 5 minutes after in the absence of agonist.

All drugs were made up as concentrated stock solutions in distilled water and stored in aliquots at −20 °C until use. Stocks were thawed once and diluted into the superfusing solution. Nucleotide analogues were obtained from Sigma (Poole, U.K.). 2-Methylthio ATP (2-MeSATP) and Pyridoxalphosphate-6-azophenyl-2’,4’-disulphonic acid (PPADS) were obtained from Tocris Cookson (Bristol, U.K). PTX (Sigma) was dissolved in 50% Glycerol containing Tris 50mM, Glycine 10mM, NaCl 0.5M, pH 7.5.

Data analysis- Ca\(^{2+}\) entry in chromaffin cells was determined by integration of \(I_{Ca}\), the left limit was set ~ 3 ms into the voltage pulse, to exclude the major portion of the contaminating Na\(^{+}\) current. \(\Delta C_m\) measurements were performed as described previously (Powell et al. 2000). Concentration response data obtained from individual cells were fitted with the Hill equation: \(Y = ((X)^H\cdot M)/((X)^H + (EC_{50})^H)\) where \(Y = \) response, \(X = \) agonist concentration, \(H\) is the Hill coefficient, \(M\) is maximum response and \(EC_{50}\) is the concentration of agonist evoking 50% of the maximum response. \(pEC_{50}\) is the \(-\log_{10}\) of the \(EC_{50}\) value. Data are presented as mean ± s.e.m. and differences between means were tested using either paired or independent Student’s t-test, as appropriate.
RESULTS

**Measurements of $I_{Ca}$ in chromaffin cells.** The effects of adenosine and uridine nucleotides on $I_{Ca}$ in bovine chromaffin cells were examined (Figure 1). Currents were activated every 30 sec with step depolarizations to +20 mV from a holding potential of -90 mV. Superfusion with ATP or the P2Y selective analogue, 2-MeSATP had no effect on the holding current but reversibly inhibited $I_{Ca}$ by $45 \pm 3\%$ (100 µM ATP, n=13) and $44 \pm 4\%$ (100 nM 2-MeSATP, n=11). UTP (100 µM) also inhibited $I_{Ca}$ ($36 \pm 6\%$, n=11) without changing the holding current. Preceding the test pulse by a 20 ms depolarizing prepulse to 120 mV reduced the inhibitory effect of 2-MeSATP to $15.5 \pm 3.5\%$ (n=3) and of UTP to $8 \pm 2\%$ (n=3) (Figure 1C). The voltage-dependence of the inhibitory effect was also observed by examining the effect of 2-MeSATP on the current-voltage relationship (data not shown). Inhibition of $I_{Ca}$ by 2-MeSATP was significantly reduced at potentials positive to +30 mV. Furthermore, 2-MeSATP produced a significant depolarizing shift in the activation curve ($V_{50}$ control $14.8 \pm 3.7$ mV, 2-MeSATP $22.4 \pm 4.7$ mV, n=6 p<0.05). The voltage-sensitivity of the inhibitory effects of the purines and pyrimidines on $I_{Ca}$ is consistent with a signalling pathway that involves direct modulation of the channels by $G_{i/o}$ subunits (Dolphin, 2003). Treatment of chromaffin cells with PTX (250 ng/ml for 24 hours) completely blocked the effect of both 2-MeSATP ($3.5 \pm 0.8\%$; n=4) and UTP ($2.8 \pm 1.0\%$, n=4) (Figure 1D,E), confirming the sole involvement of $G_{i/o}$ coupled P2Y receptor(s) in the modulation of $I_{Ca}$. In contrast to heterologously expressed P2Y$_4$ receptors (Filippov et al., 2003), the inhibition produced by UTP in chromaffin cells was not sensitive to cell dialysis; application of 30 µM UTP (~EC$_{50}$ concentration) inhibited $I_{Ca}$ recorded in the whole-cell configuration by $15.2 \pm 2.1\%$ (n=6) and by $16.3 \pm 3.1\%$ (n=8) in the perforated-patch configuration.
Involvement of Ca$^{2+}$ mobilising P2Y or P2X receptors in VOCC inhibition. To investigate the possible contribution from Ca$^{2+}$ mobilizing P2 receptors to inhibition of VOCCs, we loaded chromaffin cells with the Ca$^{2+}$-sensitive dye Fura-2 to monitor [Ca$^{2+}$]$_i$. In 10 out of 12 cells examined, neither ATP (100µM) nor UTP (100µM) produced any increase in [Ca$^{2+}$]$_i$; in these same cells, histamine (100µM) and Angiotensin II (300nM), agonists known to activate PLC coupled receptors in chromaffin cells (Cheek et al., 1993; Teschemacher and Seward, 2000), produced robust increases in [Ca$^{2+}$]$_i$ (Figure 2). Superfusion with 2-MeSATP (100 nM) also failed to produce any significant change in basal [Ca$^{2+}$]$_i$ (n = 4; see also Figure 1 Powell et al. 2000). In two out of 12 cells, ATP produced a small increase in [Ca$^{2+}$]$_i$ (mean 186% of control). However, both of these cells were found to be relatively unresponsive to histamine (mean value of 124% of control compared with 279% for ATP/UTP non-responsive cells) and had approximately half the diameter of chromaffin cells usually selected for electrophysiological investigation. (mean membrane capacitance 7.7 ± 0.5 pF (n=20), corresponding to diameter of ~15 µm). Whether this minor population of cells corresponds to noradrenergic or cortical cells, which make up 10-20% of adrenal medullary cultures, was not investigated further. From these results we can conclude that neither Ca$^{2+}$ mobilizing P2X receptors nor PLC-coupled P2Y$_{1,2,4,6}$ receptors are functionally detectable in the majority of chromaffin cells.

Agonist profile of P2Y receptors in chromaffin cells. The relative paucity of high affinity subtype selective ligands complicates the unambiguous identification of P2Y receptors within intact tissues. The method most commonly utilised to identify native P2Y receptors is to examine the relative order of potency of numerous purine and pyrimidine analogues. We examined the efficacy of a number of commonly used purine and pyrimidine analogues to inhibit I$_{Ca}$ in chromaffin cells. Agonist profiling yielded an agonist order of potency of 2-
MeSATP ≈ 2MeSADP >> ATP ≈ ADP ≥ ATPγS > UTP ≥ UDP (Figure 3A). αβMethylene ATP and adenosine were inactive (100 µM, data not shown). 2-MeSATP, 2-MeSADP, ATP, ADP and ATPγS were full agonists with mean EC₅₀ values of (in nM): 0.49 (n=4), 0.73 (n=4), 347 (n=4), 387 (n=3) and 1170 (n=3) and Hill slopes of approximately 1 (Table 2).

The uridine nucleotides were less potent than the adenosine analogues (Table 2) and UTP was incapable of exerting a full inhibitory response (Figure 3A), suggesting that it may act as a partial agonist on a receptor with mixed purine/pyrimidine sensitivity. To test this possibility, the effects of co-application of a sub-maximal concentration of UTP (10 µM) with 2-MeSATP (10 pM - 10 nM) were tested. If UTP were acting as a partial agonist at the same receptor population as those activated by 2-MeSATP, co-application would be expected to cause a rightwards shift in the concentration response curve and a depression of the maximal response. The IC₅₀ for 2-MeSATP alone and in the presence of UTP (10 µM) however, were similar (0.22 and 0.16 nM, Figure 3B), and although a slight decrease in the maximal response was observed (2-MeSATP alone, 48 ± 3 % and 2-MeSATP and UTP, 45 ± 6 %, n=4), this was not significant (p = 0.66).

In response to prolonged activation many G-protein coupled receptors undergo desensitisation; UTP preferring P2Y₄ receptors can be distinguished from UDP preferring P2Y₆ receptors in that they show rapid desensitization (Brinson and Harden, 2001). Thus, to further characterize the UTP receptor in chromaffin cells, we examined the rate and cross-desensitization of nucleotide inhibition of I_{Ca} (Figure 4). The general protocol to study desensitisation was an initial 3 minute application of either 2-MeSATP or UTP, to evaluate the control inhibition. Subsequent to this either 2-MeSATP or UTP was applied for 15 minutes and then washed out briefly, before 2-MeSATP and UTP were re-applied to check for cross-desensitisation. With prolonged superfusion of UTP, the inhibition of I_{Ca} was reduced from 35 ± 9%, to 11 ± 6 % (Figure 4A). In the same cells, application of 2-MeSATP
inhibited $I_{Ca}$ by $48 \pm 6\%$ and $49 \pm 6\%$ (n=4) before and after perfusion with UTP, showing that the decline in $I_{Ca}$ inhibition seen during perfusion with UTP was not due to rundown of the channels but desensitisation of the receptor. Moreover, since the response to 2-MeSATP was unaffected by desensitisation of the UTP response, we can conclude that there is no cross-desensitisation of the purine and pyrimidine preferring receptors in these cells. The desensitised response of UTP did not recover following an 11 minute wash period. In the converse experiment it was noted that the inhibitory effect of 2-MeSATP on $I_{Ca}$ did not undergo such pronounced desensitisation (Figure 4B). 2-MeSATP maximally inhibited $I_{Ca}$ by $43 \pm 3\%$, during the 15 minute superfusion the mean inhibition was reduced to $29 \pm 4\%$ (n=4). The response to a second application of 2-MeSATP after an 11 minute wash period was back to $37 \pm 6\%$. The size of the response to UTP (100 $\mu$M) was slightly decreased on the second application ($28 \pm 13\%$ versus $19 \pm 9\%$, n=4) however, this was not significant.

**Antagonist-sensitivity of P2Y receptors in chromaffin cells.** The agonist selectivity and PTX-sensitivity of the P2Y receptor(s) expressed in bovine adrenal chromaffin cells do not match that reported for any single cloned mammalian P2Y receptor. We therefore proceeded to examine the antagonist selectivity of the receptor(s). PPADS has been shown to be an antagonist at P2Y$_1$, P2Y$_2$, P2Y$_6$ and P2Y$_{13}$ receptors (Marteau et al., 2003), but not at P2Y$_4$ receptors (Charlton et al., 1996;Boyer et al., 1994) or human P2Y$_{12}$ receptors (Takasaki et al., 2001). PPADS antagonized the inhibitory effects of 2-MeSATP (1 nM) and UTP (30 $\mu$M) in a reversible manner. Schild analysis of PPADS antagonism of 2-MeSATP inhibition of $I_{Ca}$ showed that the antagonist was acting in a competitive manner with an apparent pA$_2$ value of $6.42 \pm 0.33$ (Figure 5A). Examination of whether PPADS produced competitive antagonism of the UTP-induced inhibition of $I_{Ca}$ was not carried out because of the low potency of UTP. Finally we examined the ability of the antithrombotic drug ARC69931MX, reported to be
selective for P2Y_{12} and P2Y_{13} receptors (Ingall et al., 1999; Marteau et al., 2003), to antagonize the regulation of I_{Ca} in chromaffin cells. Superfusion with ARC69931MX (1µM) for 1-3 minutes had no effect on I_{Ca} (106 ± 12 % of control, n=4), but in the same cells largely abolished the inhibition produced by ATP (100µM) from 49 ± 4% to 6 ± 5 % (n=4). Schild analysis of ARC69931MX antagonism of 2-MeSADP inhibition of I_{Ca} gave an apparent pA_{2} value of 9.90 ± 0.06. Inhibition of I_{Ca} by 30µM UTP however persisted in the presence of ARC69931MX (mean 20 ± 9 %, n=3), supporting the notion that distinct ATP and UTP receptors are expressed by chromaffin cells.

**Measurements of exocytosis in chromaffin cells.** An increase in C_{m} follows vesicle fusion after Ca^{2+} entry and provides a measurement of exocytosis corresponding to 2fF per vesicle fusion. We therefore utilised C_{m} measurements to determine the effects of VOCC inhibition by nucleotides on exocytosis from bovine chromaffin cells (Figure 5B and C). Application of ATP (100 µM) resulted in a marked decrease in vesicle fusion (Figure 5B). This inhibitory effect of ATP on exocytosis was completely blocked by the P2Y_{12} specific antagonist ARC69931MX (Figure 5C).

**Cloning of the bovine P2Y_{12} receptor.** Taken together the pharmacological data obtained from bovine chromaffin cells suggest that the purine receptor responsible for inhibition of I_{Ca} and exocytosis is most similar to that of P2Y_{12} or P2Y_{13} except that ATP was a full agonist rather than a weak partial agonist (Marteau et al., 2003) and PPADS is an antagonist. Unlike the pharmacology of the nucleotide responses observed in the P2Y receptors expressed in bovine chromaffin cells, human P2Y_{13} is unresponsive to both 2-MeSATP and ATP (Communi et al., 2001). Human P2Y_{12} however is responsive to 2-MeSATP in the nM range and ATP in the µM range (Takasaki et al., 2001). We therefore cloned the bovine P2Y_{12}
receptor in order to compare its pharmacology with the purine sensitive G_{i/o} coupled P2Y receptor expressed in bovine chromaffin cells. A PCR product of 1145bp was amplified from bovine chromaffin cell cDNA using the primers 2ndby12fullfor and 2ndby12fullrev. This sequence is available in the EMBL database under the accession number AJ623293. The sequence contained an open reading frame of 339 amino acids with a consensus Kozak sequence at the starting methionine. CLUSTAL alignment of the deduced bovine P2Y_{12} amino acid sequence with human, rat and mouse P2Y receptors confirmed that this sequence corresponds to P2Y_{12} and not to a related receptor such as P2Y_{13} or P2Y_{14} (Figure 6A). The cloned bovine receptor showed strong sequence identity to the known mammalian P2Y_{12} sequences with percent identities of 89.4, 84.4 and 85.9% for human, rat and mouse P2Y_{12} sequences respectively. Alignment of the human and bovine P2Y_{12} amino acid sequences (Figure 6B) demonstrates the positions of the 37 residues that differ between species. There are no differences in amino acid sequence in the region from TM6 through to TM7, a region that has been previously implicated in agonist binding in the P2Y_{2} receptor (Erb et al., 1995)

**Measurements of potassium currents in Xenopus oocytes expressing the bovine P2Y_{12} receptor.** Co-expression in *Xenopus* oocytes of the cloned cardiac inward rectifier subunits Kir 3.1 and Kir 3.4 resulted in robust expression of an inwardly rectifying potassium channel (Fig 7A). Activation of this channel by G_{b,y} release was utilised to characterise the pharmacology of the cloned bovine P2Y_{12} receptor. In order to confirm the absence of endogenous oocyte channels or receptors that could interfere with results by coupling to the exogenous bovine P2Y_{12} receptor or rat Kir channels, non-injected oocytes, and oocytes injected with cRNA for the bovine P2Y_{12} receptor only or only the Kir 3.1 and Kir 3.4 cRNAs were tested. These oocytes showed no nucleotide evoked currents (data not shown). When oocytes were co-injected with cRNAs for the bovine P2Y_{12} receptor (50 pg) and rat Kir 3.1
+3.4 channels (1.25 ng each) nucleotide evoked currents were observed. These currents reached a peak within 30 seconds, did not desensitise with the continued agonist application and decayed back to baseline within 3 minutes of agonist removal.

Concentration response data where obtained by utilising the voltage protocol depicted in Figure 7A (and described in detail in materials and methods). Similar to the agonist profile obtained in bovine chromaffin cells, ATP and ADP were essentially equipotent at the cloned bovine P2Y12 receptor showing EC50 values of 3.74 μM (pEC50 5.47 ± 0.10) and 1.56 μM (pEC50 5.97 ± 0.17) respectively (Figure 7B). 2-MeSADP and 2-MeSATP were considerably more potent with EC50 values of 0.28 nM (pEC50 9.55 ± 0.10) and 0.84 nM (pEC50 9.31 ± 0.21) respectively. Uridine nucleotides showed varying degrees of potency with UDP a full agonist (EC50 105.5 μM, pEC50 4.12 ± 0.64), UTP a very weak partial agonist (~10% maximal UDP response with 10mM UTP) and UMP inactive.

The effects of the antagonists ARC69931MX and PPADS were also determined at the cloned P2Y12 receptor in Xenopus oocytes (Figure 7C). The P2Y12 specific antagonist ARC69931MX completely blocked responses of the bovine P2Y12 receptor to 10μM ADP (IC50 0.78 nM, pIC50 8.67 ± 0.06) and 10 μM ATP (IC50 2.1 nM pIC50 9.14 ± 0.44). Furthermore, the responses to 1 mM UDP, a concentration normally eliciting a 100% response, was blocked completely by 1 μM ARC69931MX (n=4 oocytes, data not shown). PPADS, a non-specific P2 receptor antagonist blocked responses to 1nM 2MeSATP with an IC50 of 1.71 μM (pIC50 5.80 ± 0.05).

Detection of P2Y receptor mRNA in bovine chromaffin cells by RT-PCR. Of the nine known mammalian P2Y receptors (P2Y1, 2, 4, 6, 11, 12, 13, 14 and 15) it was possible to design sequence specific primers for Bovine P2Y1, 2, 6, 12 and 14 (Table 1). Amplicons of the expected size were obtained for all primer pairs when PCR was performed on bovine genomic DNA (data not
shown). Three primer pairs (P2Y\(_{1,12}\) and \(14\)) gave amplicons of the expected size when RT-PCR was performed on first strand cDNA prepared from isolated bovine chromaffin cells (Figure 8). Faint bands were observed in amplifications using P2Y\(_2\) and P2Y\(_6\) primers. However these bands were not of the correct size and are therefore likely to correspond to non specific amplifications. No bands were observed in control reactions minus reverse transcriptase confirming the absence of contaminating genomic DNA. Thus, from the RT-PCR analysis, transcripts for P2Y\(_{1,12}\) and \(14\) but not P2Y\(_2\) or P2Y\(_6\) could be detected in bovine chromaffin cells.

DISCUSSION

Like other classical neurotransmitters, it is now clear that post-synaptic receptors for nucleotides exist as either ligand-gated ion channels (ATP sensitive P2X receptors), ideally suited to rapid neurotransmission, or G protein coupled P2Y receptors, suited to slower modulatory roles. Evidence for presynaptic nucleotide receptors in the peripheral and central nervous system is also accumulating (Cunha and Ribeiro, 2000; Boehm and Kubista, 2002; Zhang et al., 2003). Positive identification of the receptor subtypes mediating presynaptic effects of nucleotides has however, been complicated by a lack of selective pharmacological tools and paucity of data from receptor knockout studies. We have shown previously that activation of a PTX-sensitive G\(_{i/o}\) protein-coupled P2Y receptor in adrenal chromaffin cells inhibits exocytosis and Ca\(^{2+}\) entry through N-type and P/Q-type VOCCs (Powell et al., 2000), a similar mechanism is thought to underlie purinergic presynaptic inhibition of sympathetic neurotransmission. In this study, we have identified one of the inhibitory receptors in chromaffin cells as P2Y\(_{12}\). In addition, we have found evidence for a second UTP-preferring receptor which acts in a similar manner. The modulation of VOCCs in chromaffin cells by both nucleotide receptors showed all the characteristic properties of G\(_{i/o}\) signalling, namely
sensitivity to voltage and PTX (Dolphin, 2003). This signalling pathway is known to be membrane-delimited, independent of diffusible second messengers and to involve direct coupling between the receptor, G_{i/o} βγ subunits and intracellular domains found on the α1A and α1B pore forming subunits that make up neuronal N- and P/Q-VOCCs.

Similar inhibition of N-type VOCCs by heterologously expressed P2Y_{12} and the closely related P2Y_{13} receptor has also been reported (Simon et al., 2002; Kubista et al., 2003; Wirkner et al. 2004). In the chromaffin-like pheochromocytoma (PC12) cell line, inhibition of N-type channels by a P2Y_{12}-like receptor is found at the cell soma (Vartian and Boehm, 2001; Kubista et al., 2003) as well as in processes (Kulick and von Kügelgen, 2002) where it contributes to an autocrine-paracrine inhibitory loop regulating exocytotic nucleotide release (Moskvina et al., 2003). One notable difference between the PC12 receptor and bovine P2Y_{12} receptor is sensitivity to PPADS, we found it to be a competitive antagonist of the bovine receptor where as in PC12 cells, which are rat derived, it is reported to be ineffective (Vartian and Boehm, 2000; Kulick and von Kügelgen, 2002; Unterberger et al., 2002). Species differences in the pharmacology of other P2Y receptor subtypes have been reported previously (Sak and Webb, 2002).

In this study, we describe the cloning and characterisation of a new member of the mammalian P2Y receptor family: bovine P2Y_{12}. At the amino acid level, the bovine receptor is similar to human P2Y_{12} with 89% of residues identical between species (compared with 85% between human and rat P2Y_{12}). The agonist selectivity of the receptor however showed some slight differences to that reported for the human P2Y_{12} receptor, most notably for ATP and UDP. Whether ATP acts as an agonist at human P2Y_{12} is unclear and most likely depends on cell type and receptor density. At purified and reconstituted human P2Y_{12}, where nucleotide breakdown has been eliminated, ATP is not an agonist but a low-affinity antagonist (Bodor et al., 2003). However, recombinant human P2Y_{12} expressed in Chinese
hamster ovary cells shows an EC₅₀ for ATP (~1µM) similar to that reported for native rat P2Y₁₂ in brain endothelial capillary cells (Simon et al., 2002) and to values reported here for bovine P2Y₁₂ in chromaffin cells and oocytes. In those studies where ATP was reported as a P2Y₁₂ agonist, ATP potency is an order of magnitude lower than ADP (Simon et al., 2002). At bovine P2Y₁₂ however, in both native bovine chromaffin cells and *Xenopus* oocytes co-expressing recombinant bovine P2Y₁₂ with rat inward rectifying potassium channels, ATP acts as a full agonist equipotent to ADP. Nucleotide breakdown of ATP to ADP can be excluded as an explanation of the bovine P2Y₁₂ ATP response since for this to be the case, it would require that 100% of ATP be instantaneously broken down by *Xenopus* oocytes and bovine chromaffin cells in a constant perfusion system and in any case, in the bovine chromaffin cell system ATP was actually slightly more potent than ADP.

A second difference in agonist selectivity between bovine and human P2Y₁₂ was the sensitivity to UDP. UDP is inactive at human P2Y₁₂ (Takasaki et al., 2001; Hollopeter et al., 2001). However, at bovine P2Y₁₂ expressed in *Xenopus* oocytes, UDP is full agonist, all be it with a low potency (EC₅₀ ~100µM). Whilst unlikely, a contamination of the commercial UDP stocks used in this study with 1% ADP or ATP would be enough to explain the UDP sensitivity observed. In order to rule out this possibility we performed HPLC on UDP alone and on UDP spiked with ATP and ADP. No contaminating peak in the sample was above 0.01% and no contaminating peak corresponded to either ATP or ADP. We also observed a small response to UTP in bovine P2Y₁₂ expressed in *Xenopus* oocytes (~10% maximal response to 10mM UTP) at such high concentrations of UTP, the possibility that responses were due to breakdown of UTP to UDP could not be ruled out.

The UTP receptor inhibiting I_{Ca} and exocytosis in chromaffin cells has not been identified at the molecular level. UTP does not appear to be acting as a partial agonist at the
bovine P2Y12 receptor since it was insensitive to ARC69931MX, caused no shift in the 2-MeSATP concentration-response curve and showed no cross-desensitisation with the purine receptor in chromaffin cells, and had a very low potency at the cloned receptor. Heterologously expressed P2Y2,4,6 receptors have also been shown to inhibit I_{Ca} in a neuronal expression system (Filippov et al., 2003; Filippov et al., 1999). However there are notable differences between the results from the expression studies and those found with the endogenous receptor in chromaffin cells, thus even when over expressed in neurones P2Y2,4,6 maintain their ability to couple to PTX-insensitive G_q proteins and inhibit M potassium currents which would lead to an increase in [Ca^{2+}]_i. UTP does not cause calcium mobilization or entry in chromaffin cells, indicating that it is not acting through a G_q or PLC-coupled receptor in these cells. Furthermore, inhibition of I_{Ca} by heterologously expressed P2Y4 is lost in whole cell recording of neurones, where as the receptor in chromaffin cell showed no such sensitivity to intracellular dialysis. In view of the fact that a positive RT-PCR result was obtained for P2Y14 expression in bovine chromaffin cells (Figure 8), we considered the possibility that UTP could be acting as a low potency agonist at the bovine P2Y14 receptor in chromaffin cells. However, UDP-glucose, the cognate ligand for human P2Y14, gave no response when tested in bovine chromaffin cells (unpublished data). Thus, either bovine P2Y14 does not couple to VOCCs in bovine chromaffin cells or the P2Y14 RT-PCR product originated from non translated mRNA in chromaffin cells or from P2Y14 in a contaminating cell type. It is interesting to note that UTP inhibition of VOCCs has been observed in parasympathetic neurones (Abe et al., 2003) and evidence for a presynaptic inhibitory UTP receptor on sympathetic nerves of the rat and mouse vas deferens has also been reported (Von Kügelgen et al., 1989; Forsyth et al., 1991). Further studies will be required to determine whether one of the still-orphaned GPCRs that share significant sequence identity with the
P2Y₁₂ receptor represent a pyrimidine selective G<sub>i/o</sub> coupled P2Y receptor in the ever growing P2 receptor family.

Finally, the results from this study confirm that P2Y₁₂ receptors, the targets of antithrombotic agents, are not restricted to platelets but are also expressed in neuro-endocrine cells where they act as inhibitory receptors to regulate the activity of neuronal VOCCs and vesicular neurotransmitter release. Expression of these receptors at nerve terminals could serve as an important autocrine inhibitory feedback loop to regulate neurotransmission in the periphery and mediate heterosynaptic suppression in the central nervous system.

ACKNOWLEDGMENTS

This work was supported by a project grant to SJE from the Biotechnology and Biological Sciences Research Council, a studentship to ADP from the Medical Research Council and a project grant to EPS from the Wellcome Trust. We thank Dr Tania Webb for help and advise with the cloning the bovine P2Y₁₂ receptor and preparation of the manuscript, Professor Mark Boyett for providing the Kir 3.1 and Kir 3.4 plasmids, Professor Mike Boarder for help with HPLC analysis of nucleotides, Professor Alan North for critical review of the manuscript and AstraZeneca for the kind donation of ARC69931MX.
Legends

Fig. 1. P2Y inhibition of I_{ca} in adrenal chromaffin cells. A, representative current traces from a single cell demonstrating ATP (10 µM) inhibition of I_{ca} evoked by 20 ms voltage steps from -90 mV to a test potential of +20 mV at a frequency of 0.067 Hz. Currents were recorded at time points illustrated in B. The rapidly inactivating (< 3ms) inward currents seen at the beginning of the traces are due to opening of TTX-sensitive voltage-activated Na⁺ channels; these currents have been truncated for illustrative purposes only. B, diary plots of the effect of ATP on normalized Ca²⁺ entry (filled circles) as measured by integrating I_{ca}, and corresponding holding current (open circles), measured at -90 mV, 3 ms prior to application of the voltage step. Data shown are the mean of four cells ± s.e.m. The time of agonist application is indicated by the bar above the graph. C, superimposed current traces recorded in a single chromaffin cell before (solid grey line) and during (solid black line) application of UTP (100 µM) in response to a 20 ms test pulse from -90 mV to +20 mV. Preceding the test pulse by a 20 ms depolarization to +120 mV (dashed line) reversed the inhibition by UTP. D, superimposed current traces from a PTX-treated chromaffin cell before (solid grey line, labelled C) and during application of UTP (100 µM) (solid black line). E, superimposed current traces from another PTX treated chromaffin cell recorded before (solid grey line, labelled C) and during application of 2-MeSATP (100 nM) (solid black line). PTX treatment completely blocked the inhibitory effects of nucleotides of I_{ca}.

Fig. 2. Involvement of Ca²⁺ mobilising P2 receptors. A, Representative fluorescence measurements of cytosolic [Ca²⁺], changes measured with Fura 2 (expressed as the ratio of emission at 340/380 nm) from a single un-clamped chromaffin cell following perfusion with ATP (100 µM), UTP (100 µM), histamine (100 µM) and Angiotensin II (300 nM) as indicated
by bars above the trace. B, Mean change in resting \([\text{Ca}^{2+}]_r\), produced by the indicated agonists for \(n=10\) cells. Neither ATP nor UTP elicits a change in resting \([\text{Ca}^{2+}]_r\), in chromaffin cells.

**Fig. 3.** Concentration-response curves for the inhibition of \(I_{\text{Ca}}\) by various nucleotides. A, the percentage inhibition in integrated \(\text{Ca}^{2+}\) entry through \(I_{\text{Ca}}\) produced by a series of nucleotide agonists is shown. Each agonist concentration was applied for 2-3 minutes until an equilibrium response was observed, and then washed for 5-10 minutes to ensure full reversal of the inhibition. All points represent the mean ± s.e.m of 3-15 chromaffin cells, lines drawn through the data represent the best fit to the Hill equation. B, effect of UTP on the concentration-response curve for 2-MeSATP inhibition of \(I_{\text{Ca}}\). Each point represents the mean ± s.e.m of 4 cells. UTP (10 \(\mu\)M) was co-applied for 2 min with increasing concentrations of 2-MeSATP (10 pM – 10 nM). UTP did not change the maximum response produced by 2-MeSATP, showing that the responses were non-additive, nor did it produce a significant shift in the concentration-response curve.

**Fig. 4.** Inhibition of VOCCs by 2-MeSATP and UTP differ in their desensitisation characteristics. VOCCs were evoked at a frequency of 0.067 Hz by a 20 ms depolarisation from -90 mV to +20 mV. Data shown are the means of three separate experiments. A, 2-MeSATP (100 nM) was applied for 2 min and then washed out. UTP (100 \(\mu\)M) was then continuously applied for 15 min to induce desensitisation of the response. At the end of the 15 minute desensitisation period, 2-MeSATP was re-applied for a further 2 minutes to examine whether cross desensitisation had occurred. A further UTP application followed to determine recovery from desensitisation. B, converse experiment in which the order of agonist applications were switched, as indicated.
**Fig. 5.** P2Y₁₂ inhibition of VOCCs and exocytosis. A. Concentration response curves for the inhibition of I_{Ca} in chromaffin cells exposed to 2-MeSATP in the absence or presence of PPADS. Data in the presence of 10 µM PPADS were constrained to a Hill Slope of 1 and minimum and maximum values of 0 and 48 %, respectively (dotted line). Schild regression analysis of the data (not shown) yielded a pA₂ value of 6.42 ± 0.34. Data illustrated is the mean ± s.e.m of three such experiments.  
B1, C1 superimposed Ca²⁺ current traces recorded in a single chromaffin cell held at -90 mV and stepped for 200 ms to +20 mV before (solid grey line) and during superfusion with 100 µM ATP (solid black line), in the absence (B1, control) or presence (C1) of 1 µM ARC69931MX.  
B2, C2, corresponding ΔC_m recorded in response to currents shown in B1 and C1. Gaps in the C_m traces represent when a voltage step was applied; the increases in C_m that follow Ca²⁺ entry provide a measure of exocytosis corresponding to 2fF per vesicle fusion.

**Fig. 6.** Bovine P2Y₁₂ sequence analysis. A. Phylogenetic analysis of bovine P2Y₁₂. P2Y amino acid sequences available for human (h), mouse (m), rat (r) and bovine (b) were aligned using the programme CLUSTAL. Accession numbers for the sequences used in the alignment are as follows: mP2Y₂ P35383, rP2Y₂ P41232, bP2Y₂ O18951, hP2Y₂ P41231, mP2Y₄ Q9JJ57, rP2Y₄ O35811, hP2Y₄ P51582, mP2Y₆ Q9ERK9, rP2Y₆ Q63371, hP2Y₆ Q15077, hP2Y₁₂ Q9H244, bP2Y₁₂ AJ623293, mP2Y₁₂ Q9CPV9, rP2Y₁₂ Q9EPX4, hP2Y₁₃ Q9BPV8, mP2Y₁₃ NP_083084, mP2Y₁₄ Q9ESG6, rP2Y₁₄ O35881, hP2Y₁₄ Q15391, mP2Y₁ P49650, rP2Y₁ P49651, hP2Y₁ P47900, bP2Y₁ P48042, hP2Y₁₁ Q96G91. B. Alignment of the human (Hum) and bovine (Bov) P2Y₁₂ amino acid sequences. Residues differing between the two sequences are shaded in the human sequence. Transmembrane domains 1-7 are indicated as lines.
**Fig. 7.** Concentration response data for the bovine P2Y$_{12}$ receptor co-expressed with rat Kir 3.1 and Kir 3.4 channels in *xenopus* oocytes. Two-electrode voltage clamp recordings were made from oocytes expressing bovine P2Y$_{12}$, rat Kir 3.1 and rat Kir 3.4. A, Currents recorded in response to UDP, 2-MeSATP, and ATP. Oocytes were clamped at 0 mV during the initial agonist application and recovery periods between applications. One minute after agonist application commenced, the holding potential was stepped down to -60mV for 5 seconds and the peak current recorded. A ramp from -60mV to +90mV over 2 seconds was applied after the 5 second recording period. No agonist induced currents or rectification was observed in oocytes expressing bovine P2Y$_{12}$ alone. B, Concentration response curves for the bovine P2Y$_{12}$ receptor expressed in *xenopus* oocytes co-expressing the rat Kir 3.1 and Kir3.4 channels. Mean currents were normalised to 100 µM ADP (maximal response). Error bars show ± standard error. n= 5-6 oocytes. C, the sensitivity of bovine P2Y$_{12}$ to the antagonists PPADS and ARC69931 was determined in *xenopus* oocytes co-expressing the rat Kir3.1 and Kir 3.1 channels. Recordings were made at a holding membrane potential of –60mV using the protocol depicted in A. Currents in response to an EC$_{90}$ application of agonist (10 µM for ADP and ATP; 1nM for 2-MeSATP) were recorded in the presence of varying concentrations of antagonists and are expressed as a percentage of the EC$_{90}$ response obtained in the absence of antagonist. The P2Y$_{12}$ specific antagonist ARC69931MX completely blocked responses of the bovine P2Y$_{12}$ receptor to 10µM ADP and 10 µM ATP with IC$_{50}$ values of 0.78 nM (pIC$_{50}$ 8.67± 0.06) and 2.1 nM (pIC$_{50}$ 9.14 ± 0.44) respectively. PPADS, a non-specific P2 receptor antagonist blocked responses to 1nM 2-MeSATP with an IC$_{50}$ of 1.71µM (pIC$_{50}$ 5.80 ± 0.05). n=4-5 oocytes.

**Fig. 8.** RT-PCR analysis of total RNA isolated bovine chromaffin cells. Primers used corresponded to the bovine P2Y$_1$, 2, 6, 12 and 14 and are detailed in table 1. Control reactions
without reverse transcriptase (-) were run alongside cDNA templates (+) to verify that amplification was not from genomic DNA. Positive bands of the expected size were observed for P2Y1,12 and 14 (marked with asterisks). M: molecular mass marker (size in base pairs).
References


Fig. 1. P2Y inhibition of $I_{Ca}$ in adrenal chromaffin cells. A, representative current traces from a single cell demonstrating ATP (10 μM) inhibition of $I_{Ca}$ evoked by 20 ms voltage steps from -90 mV to a test potential of +20 mV at a frequency of 0.067 Hz. Currents were recorded at time points illustrated in B. The rapidly inactivating (< 3ms) inward currents seen at the beginning of the traces are due to opening of TTX-sensitive voltage-activated Na$^+$ channels; these currents have been truncated for illustrative purposes only. B, diary plots of the effect of ATP on normalized Ca$^{2+}$ entry (filled circles) as measured by integrating $I_{Ca}$, and corresponding holding current (open circles), measured at -90 mV, 3 ms prior to application of the voltage step. Data shown are the mean of four cells ± s.e.m. The time of agonist application is indicated by the bar above the graph. C, superimposed current traces recorded in a single chromaffin cell before (solid grey line) and during (solid black line) application of UTP (100 μM) in response to a 20 ms test pulse from -90 mV to +20 mV. Preceding the test pulse by a 20 ms depolarization to +120 mV (dashed line) reversed the inhibition by UTP. D, superimposed current traces from a PTX-treated chromaffin cell before (solid grey line, labelled C) and during application of UTP (100 μM) (solid black line). E, superimposed current traces from another PTX treated chromaffin cell recorded before (solid grey line, labelled C) and during application of 2-MeSATP (100 nM) (solid black line). PTX treatment completely blocked the inhibitory effects of nucleotides of $I_{Ca}$.

Fig. 2. Involvement of Ca$^{2+}$ mobilising P2 receptors. A, Representative fluorescence measurements of cytosolic [Ca$^{2+}$], changes measured with Fura 2 (expressed as the ratio of emission at 340/380 nm) from a single un-clamped chromaffin cell following perfusion with ATP (100 μM), UTP (100μM), histamine (100 μM) and Angiotensin II (300 nM) as indicated...
by bars above the trace. B, Mean change in resting $[Ca^{2+}]_{o}$, produced by the indicated agonists for $n= 10$ cells. Neither ATP nor UTP elicits a change in resting $[Ca^{2+}]_{o}$ in chromaffin cells.

**Fig. 3.** Concentration-response curves for the inhibition of $I_{Ca}$ by various nucleotides. A, the percentage inhibition in integrated $Ca^{2+}$ entry through $I_{Ca}$ produced by a series of nucleotide agonists is shown. Each agonist concentration was applied for 2-3 minutes until an equilibrium response was observed, and then washed for 5-10 minutes to ensure full reversal of the inhibition. All points represent the mean ± s.e.m of 3-15 chromaffin cells, lines drawn through the data represent the best fit to the Hill equation. B, effect of UTP on the concentration-response curve for 2-MeSATP inhibition of $I_{Ca}$. Each point represents the mean ± s.e.m of 4 cells. UTP (10 µM) was co-applied for 2 min with increasing concentrations of 2-MeSATP (10 pM – 10 nM). UTP did not change the maximum response produced by 2-MeSATP, showing that the responses were non-additive, nor did it produce a significant shift in the concentration-response curve.

**Fig. 4.** Inhibition of VOCCs by 2-MeSATP and UTP differ in their desensitisation characteristics. VOCCs were evoked at a frequency of 0.067 Hz by a 20 ms depolarisation from -90 mV to +20 mV. Data shown are the means of three separate experiments. A, 2-MeSATP (100 nM) was applied for 2 min and then washed out. UTP (100 µM) was then continuously applied for 15 min to induce desensitisation of the response. At the end of the 15 minute desensitisation period, 2-MeSATP was re-applied for a further 2 minutes to examine whether cross desensitisation had occurred. A further UTP application followed to determine recovery from desensitisation. B, converse experiment in which the order of agonist applications were switched, as indicated.
**Fig. 5.** P2Y₁₂ inhibition of VOCCs and exocytosis. A. Concentration response curves for the inhibition of I_{Ca} in chromaffin cells exposed to 2-MeSATP in the absence or presence of PPADS. Data in the presence of 10 μM PPADS were constrained to a Hill Slope of 1 and minimum and maximum values of 0 and 48 %, respectively (dotted line). Schild regression analysis of the data (not shown) yielded a pA₂ value of 6.42 ± 0.34. Data illustrated is the mean ± s.e.m of three such experiments. B1, C1 superimposed Ca^{2+} current traces recorded in a single chromaffin cell held at -90 mV and stepped for 200 ms to +20 mV before (solid grey line) and during superfusion with 100 μM ATP (solid black line), in the absence (B1, control) or presence (C1) of 1 μM ARC69931MX. B2, C2, corresponding ΔC_m recorded in response to currents shown in B1 and C1. Gaps in the C_m traces represent when a voltage step was applied; the increases in C_m that follow Ca^{2+} entry provide a measure of exocytosis corresponding to 2fF per vesicle fusion.

**Fig. 6.** Bovine P2Y₁₂ sequence analysis. A. Phylogenetic analysis of bovine P2Y₁₂. P2Y amino acid sequences available for human (h), mouse (m), rat (r) and bovine (b) were aligned using the programme CLUSTAL. Accession numbers for the sequences used in the alignment are as follows: mP2Y₂ P35383, rP2Y₂ P41232, bP2Y₂ O18951, hP2Y₂ P41231, mP2Y₄ Q9JJ57, rP2Y₄ O35811, hP2Y₄ P51582, mP2Y₆ Q9ERK9, rP2Y₆ Q63371, hP2Y₆ Q15077, hP2Y₁₂ Q9H244, bP2Y₁₂ AJ623293, mP2Y₁₂ Q9CPV9, rP2Y₁₂ Q9EPX4, hP2Y₁₃ Q9BPV8, mP2Y₁₃ NP_083084, mP2Y₁₄ Q9ESG6, rP2Y₁₄ O35881, hP2Y₁₄ Q15391, mP2Y₁ P49650, rP2Y₁ P49651, hP2Y₁ P47900, bP2Y₁ P48042, hP2Y₁₁ Q96G91. B. Alignment of the human (Hum) and bovine (Bov) P2Y₁₂ amino acid sequences. Residues differing between the two sequences are shaded in the human sequence. Transmembrane domains 1-7 are indicated as lines.
Fig. 7. Concentration response data for the bovine P2Y\textsubscript{12} receptor co-expressed with rat Kir 3.1 and Kir 3.4 channels in \textit{xenopus} oocytes. Two-electrode voltage clamp recordings were made from oocytes expressing bovine P2Y\textsubscript{12}, rat Kir 3.1 and rat Kir 3.4. A, Currents recorded in response to UDP, 2-MeSATP, and ATP. Oocytes were clamped at 0 mV during the initial agonist application and recovery periods between applications. One minute after agonist application commenced, the holding potential was stepped down to -60mV for 5 seconds and the peak current recorded. A ramp from -60mV to +90mV over 2 seconds was applied after the 5 second recording period. No agonist induced currents or rectification was observed in oocytes expressing bovine P2Y\textsubscript{12} alone. B, Concentration response curves for the bovine P2Y\textsubscript{12} receptor expressed in xenopus oocytes co-expressing the rat Kir 3.1 and Kir3.4 channels. Mean currents were normalised to 100 \textmu M ADP (maximal response). Error bars show ± standard error. n= 5-6 oocytes. C, the sensitivity of bovine P2Y\textsubscript{12} to the antagonists PPADS and ARC69931 was determined in \textit{xenopus} oocytes co-expressing the rat Kir3.1 and Kir 3.1 channels. Recordings were made at a holding membrane potential of –60mV using the protocol depicted in A. Currents in response to an EC\textsubscript{90} application of agonist (10 \textmu M for ADP and ATP; 1nM for 2-MeSATP) were recorded in the presence of varying concentrations of antagonists and are expressed as a percentage of the EC\textsubscript{90} response obtained in the absence of antagonist. The P2Y\textsubscript{12} specific antagonist ARC69931MX completely blocked responses of the bovine P2Y\textsubscript{12} receptor to 10\textmu M ADP and 10 \textmu M ATP with IC\textsubscript{50} values of 0.78 nM (pIC\textsubscript{50} 8.67± 0.06) and 2.1 nM (pIC\textsubscript{50} 9.14 ± 0.44) respectively. PPADS, a non-specific P2 receptor antagonist blocked responses to 1nM 2-MeSATP with an IC\textsubscript{50} of 1.71\textmu M (pIC\textsubscript{50} 5.80 ± 0.05). n=4-5 oocytes.

Fig. 8. RT-PCR analysis of total RNA isolated bovine chromaffin cells. Primers used corresponded to the bovine P2Y\textsubscript{1, 2, 6, 12 and 14} and are detailed in table 1. Control reactions
without reverse transcriptase (-) were run alongside cDNA templates (+) to verify that amplification was not from genomic DNA. Positive bands of the expected size were observed for P2Y<sub>1,12</sub> and 14 (marked with asterisks). M: molecular mass marker (size in base pairs).
Table 1. Primer sequences used for RT-PCR analysis of P2Y expression in bovine chromaffin cells

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
<th>Expected size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2Y</td>
<td>GCCAGCCGTTCAATG</td>
<td>CAGCCCAAATCAAGCACC</td>
<td>599</td>
</tr>
<tr>
<td>P2Y2</td>
<td>ACTTCGTCACCACCCA</td>
<td>GAAAAGCAAGAACGAG</td>
<td>275</td>
</tr>
<tr>
<td>P2Y6</td>
<td>CTACTAAGCGTGCATTTC</td>
<td>GGGAGCAGCGTACAGC</td>
<td>433</td>
</tr>
<tr>
<td>P2Y12</td>
<td>TGATCGCTACCAGAGACCACAG</td>
<td>TTCATGCAAAACCAGCAAAACTC</td>
<td>205</td>
</tr>
<tr>
<td>P2Y14</td>
<td>GCATCGGTTCCTCGGCTCA</td>
<td>TGTAGGGGATTCTGCGGAATGTTGA</td>
<td>447</td>
</tr>
</tbody>
</table>
Table 2. Pharmacological data for endogenous receptors in bovine chromaffin cells and the cloned bovine P2Y_{12} receptor expressed in *Xenopus* oocytes. EC_{50}: Concentration of nucleotide required to elicit half the maximal response. pEC_{50}: -log_{10} EC_{50} (Molar). Hill Slope: gradient of concentration response. Values show ± standard error of the mean.

<table>
<thead>
<tr>
<th></th>
<th>EC_{50}</th>
<th>pEC50</th>
<th>Hill Slope</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chromaffin cells</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-MeSADP</td>
<td>0.73 nM</td>
<td>9.14 ± 0.10</td>
<td>0.85 ± 0.14</td>
</tr>
<tr>
<td>2-MeSATP</td>
<td>0.49 nM</td>
<td>9.45 ± 0.22</td>
<td>1.13 ± 0.16</td>
</tr>
<tr>
<td>ATP</td>
<td>0.35 µM</td>
<td>6.67 ± 0.25</td>
<td>1.24 ± 0.30</td>
</tr>
<tr>
<td>ADP</td>
<td>0.39 µM</td>
<td>6.44 ± 0.12</td>
<td>0.93 ± 0.08</td>
</tr>
<tr>
<td>UDP</td>
<td>34.86 µM</td>
<td>4.48 ± 0.09</td>
<td>1.53 ± 0.35</td>
</tr>
<tr>
<td>UTP</td>
<td>14.24 µM</td>
<td>4.89 ± 0.11</td>
<td>1.92 ± 0.44</td>
</tr>
<tr>
<td>ATP γS</td>
<td>1.17 µM</td>
<td>5.99 ± 0.16</td>
<td>1.38 ± 0.13</td>
</tr>
<tr>
<td><strong>Oocytes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-MeSADP</td>
<td>0.28 nM</td>
<td>9.55 ± 0.10</td>
<td>0.63 ± 0.06</td>
</tr>
<tr>
<td>2-MeSATP</td>
<td>0.84 nM</td>
<td>9.31 ± 0.21</td>
<td>0.66 ± 0.06</td>
</tr>
<tr>
<td>ATP</td>
<td>3.74 µM</td>
<td>5.47 ± 0.10</td>
<td>0.87 ± 0.04</td>
</tr>
<tr>
<td>ADP</td>
<td>1.56 µM</td>
<td>5.97 ± 0.17</td>
<td>0.86 ± 0.11</td>
</tr>
<tr>
<td>UDP</td>
<td>105.5 µM</td>
<td>4.12 ± 0.64</td>
<td>0.91 ± 0.54</td>
</tr>
<tr>
<td>UTP**</td>
<td>50.12 µM</td>
<td>4.30 ± 0.40</td>
<td></td>
</tr>
</tbody>
</table>

**Weak Partial Agonist**
Figure 2

A

30 seconds

ATP

UP

His

AngII

F340/F380

1.0

1.5

2.0

2.5

3.0

B

% Increase

300

250

200

150

100

50

ATP

His

UTP

AngII

**

**
Figure 3

A

\[ \text{log [nucleotide]} \]

% Inhibition

\[ -13 \ -12 \ -11 \ -10 \ -9 \ -8 \ -7 \ -6 \ -5 \ -4 \ -3 \ -2 \]

B

\[ \text{log [nucleotide]} \]

% Inhibition

\[ -12 \ -11 \ -10 \ -9 \ -8 \ -7 \ -6 \ -5 \ -4 \]
Figure 4

A

B

Time (Min)

% Control

UTP
2-MeSATP
UTP
2-MeSATP

0 10 20 30 40

125% Control

UTP
2-MeSATP
UTP
2-MeSATP
Figure 5

A

% Inhibition vs. Log [nucleotide] for different concentrations of PPADS.

B1

ATP response without PPADS.

B2

Capacitance traces for ATP and control.

C1

MX response without ATP.

C2

Capacitance traces for MX, MX + ATP, and control.
Figure 6

A

B

1  M---DNLTSVAGNQCSRDYKITQVLFPPLLTYTLFFVGL  Bov
1  MQDLNLTLGNGRLCDRDYKITQVLFPPLLTYTLFFVGL  Hum
TM1
38  ITNSLAMRIFSQIRSKSNFIIFLNTVISDLMILTFPPP  Bov
41  ITNSLAMRIFSQIRSKSNFIIFLNTVISDLMILTFPPP  Hum
TM2
78  ILSDTKLGFLRAFVCQTVSVFPHTMYISISPLGLITI  Bov
81  ILSDKLGTGFLRAFVCQTVSVFPHTMYISISPLGLITI  Hum
TM3
118  DRYKTTTRPFKTANPNLLGAKLTVVIAWFMILSFLPM  Bov
121  DRYKTTTRPFKTANPNLLGAKLTVVIAWFMILSFLPM  Hum
TM4
158  IILNREPSDVKCCSFLKSLPVGLWHEIVNYCQVIPWI  Bov
161  IILNREPSDVKCCSFLKSLPVGLWHEIVNYCQVIPWI  Hum
TM5
198  NFLIVIVCTTITKELKYSVRTRGKPVKKKVNIKVF1  Bov
201  NFLIVIVCTTITKELKYSVRTRGKPVKKKVNIKVF1  Hum
TM6
238  IIAVFICFVVFARIPYTSQRTDVPCATENLYFYVK  Bov
241  IIAVFICFVVFARIPYTSQRTDVPCATENLYFYVK  Hum
TM7
278  ESTWMTILNACLDPFYYFLLLCKSFKNSLSMLRCSNSTS  Bov
281  ESTWMTILNACLDPFYYFLLLCKSFKNSLSMLRCSNSTS  Hum
TM8
318  PPSNHRKQGQSGDSPSWTPM  Bov
321  PPSNHRKQGQSGDSPSWTPM  Hum

SK L
QR N I
R VRV
RIK P A T
SL Q E G N
AP TLT
GF
ATI Y
QAV
--- M DNLTSVAGNQCSRDYKITQVLFPPLLTYTLFFVGL

Bov

Hum

ITNSLAMRIFSQIRSKSNFIIFLNTVISDLMILTFPPP

Bov

Hum

ILSDTKLGFLRAFVCQTVSVFPHTMYISISPLGLITI

Bov

Hum

DRYKTTTRPFKTANPNLLGAKLTVVIAWFMILSFLPM

Bov

Hum

NFLIVIVCTTITKELKYSVRTRGKPVKKKVNIKVF1

Bov

Hum

IIAVFFICFVVFARIPYTSQRTDVPCATENLYFYVK

Bov

Hum

ESTWMTILNACLDPFYYFLLLCKSFKNSLSMLRCSNSTS

Bov

Hum

PPSHDNRKQGQSGDSPSWTPM

Bov

Hum

This article has not been copyedited and formatted. The final version may differ from this version.
Figure 7

A

Voltage

Current $P_2Y_{12} + \text{Kir 3.1+3.4}$

- $90 \text{ mV}$
- $-60 \text{ mV}$

Current $P_2Y_{12} + \text{Kir 3.1+3.4}$

- $2 \text{ MeSATP}$
- $10 + 100 $ (nM)

Current $P_2Y_{12} + \text{Kir 3.1+3.4}$

- $10 + 100 $ (0 and 100 µM)

Current $P_2Y_{12}$ only

- $2 \text{ µA}$
- $2 \text{ sec}$

B

% Maximal current

Log [nucleotide]

2-MeSADP
2-MeSATP
ADP
ATP
UTP
UDP
UMP

C

% EC$_{50}$ current

Log [Antagonist]